<?xml version="1.0" encoding="UTF-8"?>
<NDC>
<NDCCode>
61958-3601-1
</NDCCode>
<PackageDescription>
30 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (61958-3601-1)
</PackageDescription>
<NDC11Code>
61958-3601-01
</NDC11Code>
<ProductNDC>
61958-3601
</ProductNDC>
<ProductTypeName>
HUMAN PRESCRIPTION DRUG
</ProductTypeName>
<ProprietaryName>
Bixlenvo
</ProprietaryName>
<ProprietaryNameSuffix/>
<NonProprietaryName>
Bictegravir/lenacapavir
</NonProprietaryName>
<DosageFormName>
TABLET, FILM COATED
</DosageFormName>
<RouteName>
ORAL
</RouteName>
<StartMarketingDate>
20260827
</StartMarketingDate>
<EndMarketingDate/>
<MarketingCategoryName>
NDA
</MarketingCategoryName>
<ApplicationNumber>
NDA221104
</ApplicationNumber>
<LabelerName>
Gilead Sciences, Inc.
</LabelerName>
<SubstanceName>
BICTEGRAVIR SODIUM; LENACAPAVIR SODIUM
</SubstanceName>
<StrengthNumber>
75; 50
</StrengthNumber>
<StrengthUnit>
mg/1; mg/1
</StrengthUnit>
<Pharm_Classes>
Breast Cancer Resistance Protein Inhibitors [MoA], Cytochrome P450 3A Inhibitors [MoA], HIV Capsid Inhibitors [MoA], Human Immunodeficiency Virus 1 Capsid Inhibitor [EPC], P-Glycoprotein Inhibitors [MoA]
</Pharm_Classes>
<DEASchedule/>
<Status>
Active
</Status>
<LastUpdate>
2026-08-31
</LastUpdate>
<PackageNdcExcludeFlag>
N
</PackageNdcExcludeFlag>
<ProductNdcExcludeFlag>
N
</ProductNdcExcludeFlag>
<ListingRecordCertifiedThrough>
20271231
</ListingRecordCertifiedThrough>
<StartMarketingDatePackage>
20260827
</StartMarketingDatePackage>
<EndMarketingDatePackage/>
<SamplePackage>
N
</SamplePackage>
</NDC>